The purpose of this registry is to record information on reality of anti-emetic therapies of
cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic
therapies dependent on the rate "complete and major control" of nausea and emesis in
moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin,
carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.